← Insulet overview

Insulet vs Boston Scientific: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Insulet Corporation (PODD)

Q3 2026
▲2▼2

Insulet's innovation advances but safety, legal, and growth risks mount

  • Next-gen Omnipod 6 and type 2 system show strong trial results Insulet's next-generation Omnipod 6 and a closed-loop system for type 2 diabetes delivered strong trial results, signaling a promising product pipeline that could drive future growth.

    Highlights a key positive development that could support future revenue.

  • Omnipod 5 maintains rapid growth Omnipod 5 continued its rapid growth with 33% revenue growth and a 25% larger customer base, demonstrating strong demand for the current flagship product.

    Shows ongoing strong performance of the core product.

  • FDA Class I recall raises safety and regulatory concerns The FDA classified a recall of certain Omnipod devices as Class I due to a cannula tear causing insulin under-delivery, raising serious safety and regulatory concerns that could harm reputation and sales.

    A major regulatory setback with potential financial and reputational impact.

  • Guidance cut and downgrade on slowing growth and competition Insulet cut 2026 revenue growth guidance to 20-22% on weak U.S. Type 2 retention, and JPMorgan downgraded the stock to Neutral, slashing its price target to $152 from $275, citing slowing growth, rising attrition, and competition.

    Directly impacts investor expectations and stock valuation.

July 2026
▲2▼2

Insulet's innovation advances but safety, legal, and growth risks mount

  • Next-gen Omnipod 6 and type 2 system show strong trial results Insulet's next-generation Omnipod 6 and a closed-loop system for type 2 diabetes delivered strong trial results, signaling a promising product pipeline that could drive future growth.

    Highlights a key positive development that could support future revenue.

  • Omnipod 5 maintains rapid growth Omnipod 5 continued its rapid growth with 33% revenue growth and a 25% larger customer base, demonstrating strong demand for the current flagship product.

    Shows ongoing strong performance of the core product.

  • FDA Class I recall raises safety and regulatory concerns The FDA classified a recall of certain Omnipod devices as Class I due to a cannula tear causing insulin under-delivery, raising serious safety and regulatory concerns that could harm reputation and sales.

    A major regulatory setback with potential financial and reputational impact.

  • Guidance cut and downgrade on slowing growth and competition Insulet cut 2026 revenue growth guidance to 20-22% on weak U.S. Type 2 retention, and JPMorgan downgraded the stock to Neutral, slashing its price target to $152 from $275, citing slowing growth, rising attrition, and competition.

    Directly impacts investor expectations and stock valuation.

Latest
▼3

Insulet's U.S. Type 2 Weakness and Legal Woes Weigh on Outlook

  • Securities fraud class action expands with multiple law firm filings Several law firms filed or reminded investors of a securities fraud class action alleging Insulet misled about Omnipod safety and manufacturing. The August 31 lead plaintiff deadline keeps legal risk in focus, which can pressure the stock as investors weigh potential costs and reputational damage.

    This is a new legal development that adds to regulatory risk and could hurt investor confidence.

  • Insulet cuts 2026 revenue growth guidance on weak U.S. Type 2 retention Insulet lowered its 2026 revenue growth outlook to 20-22% from a prior forecast, citing lower-than-expected use and retention among U.S. Type 2 diabetes customers. Although Q2 revenue beat estimates, the reduced guidance signals weaker future demand, which pushes the stock down.

    This is a new guidance cut that directly reduces expected future revenue and earnings.

  • JPMorgan downgrades Insulet to Neutral, slashes price target to $152 JPMorgan downgraded Insulet to Neutral from Overweight and cut its price target to $152 from $275, citing slowing U.S. growth, rising Type 2 attrition, and competition. The downgrade reflects a more cautious view on 2027, which can lead to selling pressure and lower valuation.

    This is a new analyst downgrade that directly impacts investor sentiment and valuation.

▼2▲1

Insulet's strong sales offset by FDA Class I recall and fraud lawsuit

  • Next-gen Omnipod 6 shows strong trial results Insulet reported positive clinical trial results for its next-generation Omnipod 6 automated insulin delivery system and a fully closed-loop system for type 2 diabetes. The trial showed up to 50% more automated insulin delivery and fewer manual boluses. This innovation could drive future demand and support long-term growth, pushing the stock up.

    New product pipeline news that could boost future revenue and investor confidence.

  • FDA Class I recall of Omnipod devices The FDA classified a recall of certain Omnipod 5, DASH, and Eros insulin pumps as Class I, the most serious type, due to a cannula tear that can cause insulin leakage and under-delivery. This raises safety concerns, may lead to regulatory scrutiny, and could hurt sales and reputation, pushing the stock down.

    A major regulatory setback that directly threatens patient safety and future revenue.

  • Securities fraud class action lawsuit filed A securities fraud class action lawsuit alleges Insulet misled investors about product safety and manufacturing quality. The lawsuit follows two product corrections in 2026 that caused stock drops. Legal costs and potential damages could weigh on the stock, and the lawsuit may keep investors cautious.

    New legal risk that could result in financial penalties and further erode investor trust.

  • Strong Omnipod 5 momentum vs. competition and macro headwinds Omnipod 5 continues to grow rapidly, with 33% revenue growth and a 25% larger customer base. However, intensifying competition and higher raw material and shipping costs from the Middle East conflict could limit profit margins. The strong demand supports the stock, but these headwinds may cap gains.

    Balances the positive sales momentum against real pressures that could affect profitability.

Boston Scientific Corp (BSX)

Q3 2026
▼4

Boston Scientific's 2026 Q3: cyberattack, recalls, and guidance cuts overshadow deals

  • August cyberattack hits sales and guidance An August cyberattack cost roughly $300 million in Q3 sales and $0.13 per share, forcing Boston Scientific to cut its guidance again. This was a major new setback that hurt investor confidence.

    This was a major new negative event that directly reduced sales and earnings and caused a guidance cut.

  • Multiple recalls raise regulatory and reputational risk Several product recalls, including a serious Class I ENROUTE recall, increased regulatory and reputational risk. These issues can lead to fines, sales losses, and damage to the company's reputation.

    Recalls are new negative events that add regulatory and reputational pressure on the stock.

  • EP growth stalls and key launches delayed Electrophysiology growth stalled and key product launches were delayed to 2027–28. This raised doubts about future revenue growth and competitive position.

    Stalled growth and delayed launches are new negative developments that threaten future earnings.

  • Citi downgrade on rising competition Citi downgraded Boston Scientific, citing rising competition and expected 2027 share loss to Abbott's Amulet. This analyst action reflected and reinforced negative sentiment.

    The downgrade is a new negative event that directly weighs on investor sentiment and the stock price.

August 2026
▼3▲1

Cyberattack, recalls and stalled EP growth hit BSX; new products and defense deal offer hope

  • Cyberattack disrupts orders and shipments A cyberattack disrupted orders and shipments, costing an estimated $300 million in third-quarter sales and $0.13 per share, with the full damage unclear until October 28. This directly hit near-term revenue and profit.

    This is the biggest new negative event of the period and directly explains the price pressure.

  • Class I ENROUTE recall and other recalls add pressure Multiple recalls, including a Class I ENROUTE recall, added regulatory and reputational pressure. Class I is the most serious FDA category, meaning the device may cause serious harm or death.

    This is a new escalation of previously reported recall issues and adds regulatory risk.

  • Electrophysiology growth stalls; key launches delayed Electrophysiology growth stalled, with key launches (FARAWAVE Ultra, FARAFLEX) delayed to 2027–28. This pushes out expected new revenue and keeps the company behind competitors in a key heart-rhythm market.

    This is a new setback for a major growth area and explains why investors remain cautious.

  • New products and defense contract offer future growth BSX is preparing new products (SEISMIQ 4CE, RIVOS, PRECEDENT) and won a defense contract worth up to $135.7 million. These are positive steps, but most benefits will only show up from 2027 onward.

    This is the main new positive counterweight to the negative events of the period.

Latest
▼2▲1

BSX: cyberattack cost, weak EP, new launches and a leadership reset

  • Cyberattack cost now quantified Wells Fargo estimates the August cyberattack cost about $300 million in third-quarter sales and $0.13 per share, cutting its target to $48. Shipping is restored, but the full damage is still unknown until the October 28 update, so the stock stays under pressure.

    This is the main new, concrete number behind BSX's weakness and the key uncertainty still hanging over the stock.

  • Electrophysiology growth stalls, launches pushed to 2027-28 BSX says global electrophysiology growth will be flat in the second half of 2026 because of competition and gaps in its heart-rhythm portfolio. The next big product launches, including FARAWAVE Ultra and FARAFLEX, only arrive in 2027-2028, delaying the recovery.

    It explains why a core growth engine is stalling and why the payoff from new products is still years away.

  • Product launch wave and defense contract support future growth BSX is lining up launches like the SEISMIQ 4CE catheter, FDA-cleared RIVOS and the PRECEDENT defibrillator, and won a defense health contract worth up to $135.7 million for heart procedure supplies. These add future revenue, though most benefit lands in 2027 and beyond.

    It shows the concrete new sources of growth that could offset the current weak spots.

  • Leadership reset and recall add execution risk BSX named Joseph Fitzgerald as COO and split into three segments, targeting about $500 million in annual savings by 2029, while a voluntary recall of 982 StoneSmart consoles and the retirement of a key MedSurg executive add near-term disruption. The reorganization is a bet whose payoff is only visible in 2027.

    It captures the new management and quality issues that could help or hurt depending on execution.

September 2026
▼3▲1

Cyberattack cuts guidance, Penumbra deal offsets, competition and recalls weigh

  • Cyberattack forces guidance cut The August cyberattack disrupted manufacturing and shipping, so BSX now expects to miss its 2026 sales and profit targets. The full cost is unknown, and the updated outlook comes October 28. This uncertainty pushes the stock down because investors can't yet measure the damage.

    This is the main new negative event that directly caused the guidance cut and stock drop.

  • Weak WATCHMAN and EP businesses lower 2026 outlook BSX cut its 2026 growth and earnings outlook because its WATCHMAN heart implant and electrophysiology businesses are weak. Management expects pressure into 2027, with growth below the market rate. This lowers near-term profit expectations and weighs on the stock.

    This explains the fundamental business weakness behind the lowered guidance, separate from the cyberattack.

  • Penumbra acquisition expands clot-removal business BSX agreed to buy Penumbra for $14.5 billion, adding blood-clot removal technology to its heart division. The deal will slightly reduce earnings per share at first (6-8 cents) but is expected to improve later. It signals long-term growth and supports the stock.

    This is a major new strategic move that offsets some negative sentiment and shows future growth potential.

  • Citi downgrade and new competition Citi downgraded BSX to Neutral, warning of rising competition in heart procedures and expected market-share loss to Abbott's Amulet device in 2027. New proposed guidelines could also hurt WATCHMAN sales. This adds pressure on the stock as investors worry about future growth.

    This is a fresh analyst downgrade highlighting competitive and regulatory risks that directly affect BSX's valuation.

▼3▲1

Cyberattack cuts guidance, Penumbra deal offsets, competition and recalls weigh

  • Cyberattack forces guidance cut The August cyberattack disrupted manufacturing and shipping, so BSX now expects to miss its 2026 sales and profit targets. The full cost is unknown, and the updated outlook comes October 28. This uncertainty pushes the stock down because investors can't yet measure the damage.

    This is the main new negative event that directly caused the guidance cut and stock drop.

  • Weak WATCHMAN and EP businesses lower 2026 outlook BSX cut its 2026 growth and earnings outlook because its WATCHMAN heart implant and electrophysiology businesses are weak. Management expects pressure into 2027, with growth below the market rate. This lowers near-term profit expectations and weighs on the stock.

    This explains the fundamental business weakness behind the lowered guidance, separate from the cyberattack.

  • Penumbra acquisition expands clot-removal business BSX agreed to buy Penumbra for $14.5 billion, adding blood-clot removal technology to its heart division. The deal will slightly reduce earnings per share at first (6-8 cents) but is expected to improve later. It signals long-term growth and supports the stock.

    This is a major new strategic move that offsets some negative sentiment and shows future growth potential.

  • Citi downgrade and new competition Citi downgraded BSX to Neutral, warning of rising competition in heart procedures and expected market-share loss to Abbott's Amulet device in 2027. New proposed guidelines could also hurt WATCHMAN sales. This adds pressure on the stock as investors worry about future growth.

    This is a fresh analyst downgrade highlighting competitive and regulatory risks that directly affect BSX's valuation.

▼2

BSX hit by cyberattack and recalls as growth outlook weakens

  • Cybersecurity incident disrupts orders and shipments BSX disclosed a cyberattack that disrupted IT systems worldwide, hurting its ability to process and ship customer orders. The stock fell as much as 5.9% in one day. The financial cost is still unknown, so investors face uncertainty about lost sales and cleanup expenses.

    This is the biggest new event of the period and directly explains the sharp price drop.

  • New worldwide recalls add regulatory and reputational pressure BSX issued multiple recalls, including a serious Class I recall of its ENROUTE neuroprotection system and Class II recalls of OverStitch devices. These affect high-risk procedures and could disrupt hospital ordering. Recalls raise costs, invite regulatory scrutiny, and can damage trust with doctors and patients.

    This is a fresh negative event that adds to the company's operational and reputational problems.

July 2026
▲2▼2

BSX beat Q2 but cut guidance twice on WATCHMAN and EP share losses

  • Guidance cut twice on WATCHMAN weakness and lost EP share Boston Scientific lowered its 2026 outlook twice, blaming weak demand for its WATCHMAN heart implant and lost U.S. electrophysiology market share. This directly hurt investor confidence and near-term profit expectations.

    The repeated guidance cuts are the main negative force on the stock this period.

  • Q2 beat and $500M restructuring savings plan The company beat second-quarter estimates and launched a restructuring aimed at saving $500 million a year by 2029. Cost cuts can protect profits while sales growth is slow.

    This is a new positive offset to the weak demand and share-loss news.

  • $1.5B MiRus stake and $3B TAVR option Boston Scientific invested $1.5 billion for a 34% stake in MiRus and secured an exclusive $3 billion option to buy a TAVR heart-valve business. This expands its cardiology pipeline for future growth.

    A major new capital deployment that supports the longer-term growth story.

  • Multiple recalls raise safety and regulatory concerns Recalls hit CRE endoscopy devices, ENROUTE catheters (FDA warning after tip separation), FARADRIVE ablation generators, vascular sheaths, and Orca valves. These quality problems add regulatory and reputational risk.

    The wave of recalls is a new negative that weighs on trust and future sales.

▼3▲1

BSX cuts 2026 outlook on WATCHMAN and EP weakness; recalls add pressure

  • 2026 guidance cut on WATCHMAN and electrophysiology weakness Boston Scientific lowered its 2026 sales growth and earnings guidance, citing weaker WATCHMAN heart-implant demand and lost U.S. electrophysiology market share. This directly reduces expected future profits, pushing the stock down as investors reprice slower growth.

    This is the core new event that answers why BSX is moving now.

  • New recalls of cardiac ablation generators and vascular sheaths Boston Scientific recalled cardiac ablation generators and vascular sheaths due to labeling errors and air embolism risks, covering over 700,000 FARADRIVE units. This raises regulatory and safety concerns, potentially hurting sales and reputation in key heart-rhythm products.

    A fresh recall event that adds to negative pressure on the stock.

  • $1.5B MiRus investment with TAVR acquisition option Boston Scientific invested $1.5 billion for a 34% stake in MiRus and gained an exclusive option to buy its advanced TAVR heart-valve system for $3 billion. This expands its interventional cardiology pipeline with a less invasive option, supporting longer-term growth.

    A new strategic investment that could lift future growth prospects.

  • Nationwide recall of Orca valves Boston Scientific voluntarily recalled its Orca Single Use Air/Water and Suction Valves nationwide after a device malfunction. This adds operational and regulatory scrutiny, potentially disrupting hospital procedures and weighing on near-term sales.

    A new recall event that contributes to the negative news flow.

▼2▲1

BSX swings on recalls, restructuring, and mixed Q2 guidance

  • Sterile-packaging recalls raise quality and regulatory risk Boston Scientific recalled tens of thousands of CRE endoscopy devices worldwide due to sterile packaging breaches. This adds regulatory and quality-control concerns, potentially pressuring margins and brand trust in the endoscopy segment, and may reinforce worries about integration risk as the company scales.

    New recall event that introduces regulatory and quality risk, directly affecting BSX's outlook.

  • FDA warns on ENROUTE catheters after tip separation reports The FDA advised avoiding certain lots of Boston Scientific's ENROUTE catheters after reports of tip separation, including one serious injury. This raises safety and regulatory concerns, potentially leading to product liability, sales impact, and reputational damage in the neurovascular space.

    New FDA warning that adds regulatory and safety risk, directly affecting BSX's product sales and reputation.

  • Restructuring plan aims to cut $500M in annual costs Boston Scientific announced a global restructuring with job cuts, expecting $700–800 million in costs but $500 million in annual pre-tax savings by 2029. This should boost profitability and fund growth areas like FARAPULSE and WATCHMAN, though it signals pressure in some segments.

    New restructuring initiative that directly impacts future profitability and resource allocation.

  • Q2 beat but 2026 guidance trimmed, then stock rebounds Boston Scientific beat Q2 earnings and revenue estimates, but trimmed full-year EPS and sales growth guidance, initially sending shares down 5%. The next day, shares rose 7.1% as investors focused on the beat and raised sales outlook, though guidance remains below consensus.

    New quarterly results and guidance change that directly drive stock movement and investor sentiment.